Category: Thoratec Corp.
ReliantHeart touts study data finding that its HeartAssist5 left ventricular assist device poses a lower risk of blood clots and damage compared with Thoratec's HeartMate II.
FDA regulators put their highest-risk Class I label on a recall of Thoratec's HeartMate II implantable heart pump after 5 patients injuries and 4 deaths were reportedly associated with a defect in controlling the implants.
MASSDEVICE ON CALL — The FDA issued it's highest-risk Class I warning after Thoratec (NSDQ:THOR) recalled its HeartMate II implantable heart pumps over a controller issue that the FDA said was associated 4 patient deaths and 5 serious injuries.
Thoratec updates its warning about the risk of switching controllers for its HeartMate II implantable heart pump.
Thoratec (NSDQ:THOR) issued an update about a problem with its HeartMate II left ventricular assist device involved in 8 serious injuries or deaths.
Hedge fund giant BlackRock boosted its stake in a number of medical device companies last year, but cut its holdings in others, regulatory filings show.
Wright Medical Group Inc.
, Align Technology Inc.
, ArthroCare Corp.
, AtriCure Inc.
, Biolase Technology Inc.
, BlackRock Inc.
, Cutera Inc.
, Cynosure Inc.
, Dentsply International Inc.
, HeartWare International Inc.
, ICU Medical Inc.
, Medical Action Industries Inc.
, Merit Medical Systems Inc.
, NxStage Medical Inc.
, Thoratec Corp.
Thoratec warns patients with its HeartMate II heart pump about the risk of switching controllers after receiving reports of 4 deaths.
Thoratec (NSDQ:THOR) said it sent out a warning about its HeartMate II left ventricular assist device after receiving reports of 4 deaths associated with switching out the heart pump's controller.
Company officials at Thoratec discuss the company's Q4 2013 earnings call. The company reported profits of $13.1 million, or 23¢ per diluted share, on sales of $128.2 million during the 3 months ended December 28, swinging to the black on a minor dip in sales.
Thoratec gains after posting a swing to the black for its 4th quarter, driven primarily by freedom from impairment charges, and projects strong growth in 2014.
California medical device maker Thoratec (NSDQ:THOR) posted another strong quarter to cap off a year of growth in sales and fewer hits to revenues.